Seeking Alpha

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...
Morningstar

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...
The American Journal of Managed Care

Future of PsA Therapy Combination Strategies and New Endpoints

Sustained long-term safety data for tildrakizumab strengthens the positioning of IL-23 inhibitors as a preferred choice, especially for patients with comorbidities or a history of infection, and ...
Seeking Alpha

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

1 One case of infusion reaction and one case of pruritus, both Grade 1 and resolved without medication. 2 One case of asymptomatic increased lipase, isolated to Day 43 post-dose (Grade 3); One case of ...